1[2]Skubitz AP. Adhesion molecules. Cancer Treat Res, 2002, 5(2):305
2[4]Ponta H,Sherman L, Herrlich PA.CD44: from adhesion molecules to signallng regulators. Nature Rev Mol Cell Boil, 2003, 4(1):33
3[5]Jeffrey S,Ross MD, Christine E, et al. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol, 2001, 116:122
4[6]Stickeler E, Vogl FD, Denkinger T, et al. Soluble CD44 splice variants and pelvic lymph node metatasis in ovarian patients. Int J Mol Med, 2000, 6(5): 595
5[7]Dulak J, Jozkowicz A. Regulation of vascular endothelial growth factor synthesis by nitric oxide: facts and controversies. Antioxid Redox Signal, 2003, 5(1): 123
6[8]Dulak J,Fang J,Inutsuka T, et al. Vascular permeability enhancement in solid tumor.various factors, mechanisms involved and its implications. Int Immunophatmacol, 2003, 3(3): 319
7[9]Finlay CA,Hinds PW,Levine AJ, et al. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 1989, 57:1083
8[10]Jeannon JP, Somes J,Lunec J,et al. Expression of cylia-dependent kinase inhibitor p21 q (WAFI) and p53 tumor suppressor gene in laryngeal cancer. Clin Otolaryngel, 2000, 25:23
9Cemazar M, Sersa G, Wilson J, et al. Effective gene transfer to solid tumors using different nonviral gene delivery techniques:electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther, 2002, 9(4):399
10Al-Hendy A, Magliocco A M, Al-Tweigeri T, et al. Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol, 2000 Mar,182(3):
2McCorkle R, Pasaereta J, Tang ST. The silent killer: psychological issues in ovarian cancer [ J ]. Holistic Nursing Practice, 2003,17 (16) :300 -308.
3Hsu CY, Bristow R, Cha MS, et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas[ J]. Clin Cancer Res,2004,10 (19) :6423 - 6436.
4Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein[ J]. Vet Pathol,2004 ,41 ( 6 ) :599 - 607.
5Montorsi M,Maggioni M, Falleni M, et al. Survivin gene expression in chronic liver disease and hepatoceUular carcinoma [ J ]. Hepatogastroenterology ,2007,54 (79) : 2040 - 2044.
6Yang X,Xiong G,Chen X,et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol,2009, 135 (10) : 1341 - 1349.
7Yang X,Xiong G,Chen X,et al. Survivin expression in esophageal cancer:correlation with 1153 mutations and promoter polymorphism [ J ]. Dis Esophagus, 2009,22 ( 3 ) : 223 - 230.
8Jang JS, Kim KM, Kang KH, et al. Polymorphisms in the survivin gene and the risk of lung cancer[J]. Lung Cancer,2008,60( 1 ) : 31 -39.
9Huang Q, Fu YX, Boerwinkle E. Comparison of strategies for selecting single nucleotide polymorphisms for case/control association studies[J].Hum Genet ,2003,113 ( 3 ) :253 - 257.
10Rustin GJ, Quinn M, Thigpen T, et al. New guidelines to evaluate the response to treatment in solid rumors (ovarian cancer) [ J ]. J Natl Cancer Inst, 2004,96 ( 6 ) :487 - 488.
